EXPLAINED: 7 - The Real Truth

Sales in weight-loss drug Mounjaro double amid surging market appetite

Eli Lilly’s chief executive David Ricks told investors that it was ‘building for the future’

The Independent UK · Aug 5

Novo CEO says setbacks demand faster research, acquisitions as investors fret over pipeline

Novo Nordisk CEO Mike Doustdar said the company will speed up research and pursue smaller acquisitions to strengthen its drug pipeline after recent trial setbacks. The company raised its 2026 sales and profit outlook, but shares fell as investors focused on weaker-than-expected Wegovy pill sales and another setback for obesity…

The Economic Times · Aug 5

Novo Nordisk Stock Slides After Outlook Disappoints. But Wegovy Sales Continue to Climb

U.S.-listed shares of Novo Nordisk fell more than 6% after the company raised its full-year 2026 outlook but signaled that sales and profit could still decline compared with the previous year.

International Business Times · Aug 4

What Is Retatrutide? The Next-Gen GLP-1 Poised to Become the Most In-Demand Peptide

A deep dive into Retatrutide shows promise—and a lot of danger.

Marie Claire · Aug 3

Ultra-processed food companies hindering health drives by suing countries, says WHO

Exclusive: Director general accuses corporations of obstructing efforts to tackle obesity crisis after investigation by Guardian and others

The Guardian - UK · Aug 1

Alcohol’s hidden calories: product labels could help fight obesity in South Africa

South Africa is grappling with an obesity crisis. Nearly half of adults are overweight or obese. Public discussion often focuses on ultra-processed foods and sugary drinks as reasons for weight gain. But there’s another source of calories that’s often overlooked: alcoholic drinks.

The Conversation · Jul 30

GLP-1 Drugs Did Not Lower Relapse Risk in Crohn's and Colitis Patients, a Large Claims Analysis Found

A claims study found GLP-1 drugs did not reduce IBD relapse in patients with obesity or diabetes, and did not raise safety events.

Medical Daily · Jul 29

GLP-1 Medicare Coverage: How to Get It for $50 (And the Catch)

A new CMS program finally brings Wegovy and Zepbound within reach for seniors. But a hidden rule about your deductible could cost you thousands.

Kiplinger · Jul 29

Denied Coverage For Wegovy Or Zepbound? Here Is What The Latest Value Assessment Says About Price And Access

Denied for Wegovy or Zepbound? A new value analysis explains why plans refuse coverage and what exceptions and appeals actually involve.

Medical Daily · Jul 27

ICER Finds Weight-Loss Drugs Cost-Effective, But Analysts Warn the Projected Savings Depend on Patients Staying On Them

ICER finds GLP-1s cost-effective for obesity, but analysts warn projected savings assume patients stay on treatment. What it means for coverage.

Medical Daily · Jul 27